RxDoctor Payments Data

Charles Gay, MD

Family Medicine · Bellville, TXNPI 1225008469

Payments from drug & device makers

$1,044in general payments, 2019–2025

Across 42 payments — averaging $24.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$173
  • Novo Nordisk$150
  • Boehringer Ingelheim$138
  • AstraZeneca$109
  • AbbVie$95
  • Lilly USA, LLC$87
  • plus $292 from 7 others

What the payments were for

  • Food & beverage$1,03099%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,044 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$152,723
Medicare patients
317
Services billed
2,015

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban120$87,941
OzempicSemaglutide61$78,591
JardianceEmpagliflozin79$70,617
Dupixent SyringeDupilumab15$57,128
TrulicityDulaglutide34$46,186
MounjaroTirzepatide34$39,787
XareltoRivaroxaban46$36,253
FarxigaDapagliflozin Propanediol50$35,843
EntrestoSacubitril/Valsartan30$20,429
JanuviaSitagliptin Phosphate15$17,573
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$14,806
LinzessLinaclotide19$14,560
Tresiba Flextouch U-100Insulin Degludec20$11,522
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$10,857
MyrbetriqMirabegron11$8,167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$87$85,97368 claims
Novo NordiskOzempic$150$78,59161 claims
Boehringer IngelheimJardiance$138$70,61779 claims
AstraZenecaFarxiga, Breztri Aerosphere$109$50,64966 claims
AbbVieLinzess, Synthroid, Creon$95$19,25568 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Bellville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →